Evidence map›Paper›PMID 35015509›Full record

ArticleACS infectious diseases2022

A d-Phenylalanine-Benzoxazole Derivative Reveals the Role of the Essential Enzyme Rv3603c in the Pantothenate Biosynthetic Pathway of

Michael J Pepi, Shibin Chacko, Gary M Marqus, Vinayak Singh, Zhe Wang, Kyle Planck, Ryan T Cullinane, Penchala N Meka, Deviprasad R Gollapalli, Thomas R Ioerger and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Identification of a depupylation regulator for an essential enzyme inProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Michael J PepiGraduate Program in Chemistry, Brandeis University, Waltham 02453, Massachusetts, United States.
Shibin ChackoDepartment of Biology, Brandeis University, Waltham 02453, Massachusetts, United States.
Gary M MarqusGraduate Program in Chemistry, Brandeis University, Waltham 02453, Massachusetts, United States.
Vinayak SinghDrug Discovery and Development Centre (H3D), and South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-9002-2489
Zhe WangDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York 10065, New York, United States.
Kyle PlanckDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York 10065, New York, United States.
Ryan T CullinaneDepartment of Biology, Brandeis University, Waltham 02453, Massachusetts, United States.
Penchala N MekaDepartment of Biology, Brandeis University, Waltham 02453, Massachusetts, United States.
Deviprasad R GollapalliDepartment of Biology, Brandeis University, Waltham 02453, Massachusetts, United States.
Thomas R IoergerDepartment of Computer Science and Engineering, Texas A&M University, College Station 77843, Texas, United States.
Kyu Y RheeDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York 10065, New York, United States.
Gregory D CunyDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston 77204, Texas, United States.ORCID 0000-0002-3188-4748
Helena I M BoshoffTuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Bethesda 20892, Maryland, United States.ORCID 0000-0002-4333-206X
Lizbeth HedstromDepartment of Biology, Brandeis University, Waltham 02453, Massachusetts, United States.ORCID 0000-0001-8432-3322
Brandeis University · USCornell University · USNational Institute of Allergy and Infectious Diseases · USSouth African Medical Research Council · ZATexas A&M University · USUniversity of Houston · US

Funding

Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLICKMAN, MICHAEL S, NATHAN, CARL FRANCIS · 2014 to 2020
$48.6M
Development Of New Chemotherapeutics For TuberculosisZIAAI000693 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2025
$20.1M
IMPDH inhibitors for the treatment of Cryptosporidium infectionsR01AI125362 · NIAID · UNIVERSITY OF HOUSTON · PI CUNY, GREGORY D · 2016 to 2020
$3.8M
Opportunities for multi-target drug discovery in tuberculosisR21AI138048 · NIAID · BRANDEIS UNIVERSITY · PI HEDSTROM, LIZBETH K. · 2019 to 2020
$445k
NIAID NIH HHS R01 AI125362NIAID NIH HHS R21 AI138048NIAID NIH HHS U19 AI111143
6 · The paper itself

Abstract

New drugs and new targets are urgently needed to treat tuberculosis. We discovered that d-phenylalanine-benzoxazole

Indexed as

Mycobacterium tuberculosisBenzoxazolesBiosynthetic PathwaysCoenzyme APhenylalanineBenzoxazolesCoenzyme APhenylalanine2-dehydropanoate 2-reductasecoenzyme AIlvCketopantoate reductasePanGTatABC

Identifiers

PMID35015509
PMCPMC9558617
OpenAlexW4205745924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.